Do Analysts Agree Wednesday on Lyell Immunopharma Inc (LYEL) Stock's Target Price?

Wednesday, March 20, 2024 12:36 PM | InvestorsObserver Analysts

Mentioned in this article

InvestorsObserver is giving Lyell Immunopharma Inc (LYEL) an Analyst Rating Rank of 30, meaning LYEL is ranked higher by analysts than 30% of stocks. The average price target for LYEL is $6 and analyst’s rate the stock as a Buy.

Wall Street analysts are rating LYEL a Buy today. Find out what this means to you and get the rest of the rankings on LYEL!
See Full LYEL Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Lyell Immunopharma Inc Stock Today?

Lyell Immunopharma Inc (LYEL) stock has risen 1.26% while the S&P 500 is down -0.04% as of 12:22 PM on Wednesday, Mar 20. LYEL has risen $0.03 from the previous closing price of $1.99 on volume of 401,765 shares. Over the past year the S&P 500 has risen 29.31% while LYEL is down -8.18%. LYEL lost -$0.93 per share the over the last 12 months. Click Here to get the full Stock Report for Lyell Immunopharma Inc stock.

Share this article:

Related Articles